---
title: "晖致第二季度财报即将发布：有哪些值得期待的内容"
description: "制药公司晖致（NASDAQ:VTRS）将在周四公布其第二季度财报，华尔街预计每股收益（EPS）为 0.56 美元，下降 19%，收入为 34.6 亿美元，下降 9%。晖致在过去一年中 75% 的时间里超出了每股收益和收入的预期。该股今年已下跌近 29%，主要归因于产品线的挫折和研发失败，导致分析师将其评级为持有。最近的修订显示每股收益和收入预期的变化喜忧参半"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/251864780.md"
published_at: "2025-08-06T14:32:46.000Z"
---

# 晖致第二季度财报即将发布：有哪些值得期待的内容

> 制药公司晖致（NASDAQ:VTRS）将在周四公布其第二季度财报，华尔街预计每股收益（EPS）为 0.56 美元，下降 19%，收入为 34.6 亿美元，下降 9%。晖致在过去一年中 75% 的时间里超出了每股收益和收入的预期。该股今年已下跌近 29%，主要归因于产品线的挫折和研发失败，导致分析师将其评级为持有。最近的修订显示每股收益和收入预期的变化喜忧参半

Pharmaceutical company Viatris (NASDAQ:VTRS) is set to announce its second quarter earnings result on Thursday, before the opening bell. Wall Street expects the Pennsylvania-based drugmaker to post EPS of $0.56, implying a fall of nearly 19% while revenue is expected to decline about 9% to $3.46 billion during the quarter. Over the last one year, V...

### Related Stocks

- [VTRS.US - 晖致](https://longbridge.com/zh-CN/quote/VTRS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| How Is The Market Feeling About Viatris Inc? | Viatris Inc's short interest has increased by 12.02%, with 26.26 million shares sold short, representing 2.61% of availa | [Link](https://longbridge.com/zh-CN/news/270733862.md) |
| Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer \| VTRS Stock News | Viatris Inc. has appointed Lara Ramsburg as Chief People and Corporate Affairs Officer, a role aimed at enhancing the co | [Link](https://longbridge.com/zh-CN/news/271946525.md) |
| FDA Approves Viatris Generic Version of Sandostatin LAR Depot | The FDA has approved Viatris' generic version of Sandostatin LAR Depot. The FDA also accepted Viatris' New Drug Applicat | [Link](https://longbridge.com/zh-CN/news/270153300.md) |
| Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln | Viatris Inc. announced a definitive agreement to sell its equity stake in Biocon Biologics Limited to Biocon Limited for | [Link](https://longbridge.com/zh-CN/news/268835258.md) |
| Viatris Says FDA Approves Octreotide Acetate, Clears MR-146 for Clinical Trials | Viatris announced FDA approval for octreotide acetate, a generic version of Sandostatin LAR Depot, for treating acromega | [Link](https://longbridge.com/zh-CN/news/270166060.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。
